Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis.
Saved in:
| Title: | Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. |
|---|---|
| Authors: | Hetta, Helal F.1 (AUTHOR) hhussen@ut.edu.sa, Salama, Ayman2 (AUTHOR), Aljuaid, Turki A.3 (AUTHOR), Mojmami, Yazan T.3,4 (AUTHOR), Alotibi, Riyadh S.3,5 (AUTHOR), Alqabaly, Ahmed M.1,3 (AUTHOR), Aldosari, Nawaf A.2,3 (AUTHOR), Alshahri, Sami A.3 (AUTHOR), Asiri, Walid I. A.3,4 (AUTHOR), Alamri, Raed S.3,5 (AUTHOR), Alanazi, Fayez A.3 (AUTHOR), Alenazi, Malek S. A.3 (AUTHOR), Albuhayri, Mohammed H.3 (AUTHOR), Ramadan, Yasmin N.4 (AUTHOR), Sayad, Reem5 (AUTHOR) |
| Source: | Pharmaceuticals (14248247). Mar2026, Vol. 19 Issue 3, p467. 19p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
